Advertisement News Archives - Page 3 of 5155 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

March 18, 2024

FDA committee recommends BMS-2seventy’s Abecma

The US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has voted in favour of Bristol Myers Squibb (BMS) and 2seventy bio’s Abecma (idecabtagene vicleucel) for treating triple-class exposed relapsed or refractory multiple myeloma.

FDA committee recommends BMS-2seventy’s Abecma